Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Daunorubicin + FLAG in Pediatric Relapsed/Refractory AML
NCT00186966Phase 3Completed
- Sponsor
- Dutch Childhood Oncology Group
- Start
- Mar 2002
- Primary completion
- Apr 2009
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of liposomal daunorubicin in acute myeloid leukemia (AML), sponsored by Dutch Childhood Oncology Group. Started Mar 2002; status: completed.
02
Drugs
liposomal daunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00186966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00186966.